Aroa Biosurgery Limited ARX.AX · Stock Open Aroa Biosurgery Limited in new tab
Aroa Biosurgery Limited Analysis (ARX.AX)
Is Aroa Biosurgery Limited a good investment? Aroa Biosurgery Limited (ARX.AX) is currently trading at 0.5300 AUD. Market analysts have a consensus price target of 1.06 AUD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 55.50. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Aroa Biosurgery Limited is expected to release its next earnings report on Nov. 24, 2026. The market consensus estimate for Forward EPS is 0.03.
Investor FAQ
Does Aroa Biosurgery Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Aroa Biosurgery Limited?
Aroa Biosurgery Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 24, 2026. The company currently has a trailing EPS of 0.01.
Company Profile
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symphony products for the treatment of partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds, and draining wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Community Discussion